Jason K Perry - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jason K Perry

Showing results (21-30 of 40) with videos related to

Pageof 4

Sort By:

Antimicrobial Agents and Chemotherapy|December 19, 2024

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participantsLauren Rodriguez, Hery W Lee, Jiani Li, et al.

The Journal of Infectious Diseases|July 19, 2023

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)Charlotte Hedskog, Lauren Rodriguez, Pavitra Roychoudhury, et al.

Molecules (Basel, Switzerland)|July 9, 2022

The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2Joy Y Feng, Venice Du Pont, Darius Babusis, et al.

Journal of Medicinal Chemistry|March 19, 2004

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracyRichard A Friesner, Jay L Banks, Robert B Murphy, et al.

Antimicrobial Agents and Chemotherapy|May 9, 2022

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 VariantsJared Pitts, Jiani Li, Jason K Perry, et al.

Viruses|February 27, 2026

1'- and 4'-Cyano Modified Adenosine Analogs Against Prototypic Flavivirus RNA-Dependent RNA PolymerasesSimon M Walker, Calvin J Gordon, Egor P Tchesnokov, et al.

Journal of Medicinal Chemistry|October 2, 2009

RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural informationThorsten A Kirschberg, Mini Balakrishnan, Neil H Squires, et al.

Proceedings of the National Academy of Sciences of the United States of America|October 8, 2020

Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerasesMichael K Lo, César G Albariño, Jason K Perry, et al.

Science Translational Medicine|April 28, 2022

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanismsLaura J Stevens, Andrea J Pruijssers, Hery W Lee, et al.

Journal of Medicinal Chemistry|May 15, 2020

Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis BRichard L Mackman, Michael Mish, Gregory Chin, et al.

Pageof 4

Search research articles

Showing results (21-30 of 40) with videos related to

Sort By:

Pageof 4

Antimicrobial Agents and Chemotherapy|December 19, 2024

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participantsLauren Rodriguez, Hery W Lee, Jiani Li, et al.

The Journal of Infectious Diseases|July 19, 2023

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)Charlotte Hedskog, Lauren Rodriguez, Pavitra Roychoudhury, et al.

Molecules (Basel, Switzerland)|July 9, 2022

The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2Joy Y Feng, Venice Du Pont, Darius Babusis, et al.

Journal of Medicinal Chemistry|March 19, 2004

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracyRichard A Friesner, Jay L Banks, Robert B Murphy, et al.

Antimicrobial Agents and Chemotherapy|May 9, 2022

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 VariantsJared Pitts, Jiani Li, Jason K Perry, et al.

Viruses|February 27, 2026

1'- and 4'-Cyano Modified Adenosine Analogs Against Prototypic Flavivirus RNA-Dependent RNA PolymerasesSimon M Walker, Calvin J Gordon, Egor P Tchesnokov, et al.

Journal of Medicinal Chemistry|October 2, 2009

Proceedings of the National Academy of Sciences of the United States of America|October 8, 2020

Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerasesMichael K Lo, César G Albariño, Jason K Perry, et al.

Science Translational Medicine|April 28, 2022

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanismsLaura J Stevens, Andrea J Pruijssers, Hery W Lee, et al.

Journal of Medicinal Chemistry|May 15, 2020

Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis BRichard L Mackman, Michael Mish, Gregory Chin, et al.

Pageof 4